Viewing Study NCT01256450


Ignite Creation Date: 2025-12-24 @ 5:00 PM
Ignite Modification Date: 2025-12-28 @ 10:12 PM
Study NCT ID: NCT01256450
Status: COMPLETED
Last Update Posted: 2017-02-27
First Post: 2010-12-07
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
Sponsor: BioDelivery Sciences International
Organization:

Study Overview

Official Title: A 12-Week, Placebo Controlled, Double Blind, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Buprenorphine HCl Buccal Film in Subjects With Moderate to Severe Chronic Low Back Pain
Status: COMPLETED
Status Verified Date: 2017-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine whether buprenorphine hydrochloride (HCl) buccal film is effective and safe in the treatment of chronic low back pain (CLBP).
Detailed Description: This is an enriched enrollment, randomized withdrawal study with an open label, dose-titration period followed by a randomized, double-blind, placebo-controlled treatment period of 12 weeks. During the double-blind treatment period, this study will evaluate the effectiveness of buprenorphine HCl buccal film versus placebo buccal film in treating CLBP in subjects.

Buprenorphine HCl buccal film is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa. Buprenorphine is a synthetic opioid that is classified as a partial ยต-receptor agonist and a Schedule III controlled substance in the United States.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: